MX420195B - Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos - Google Patents

Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos

Info

Publication number
MX420195B
MX420195B MX2022000939A MX2022000939A MX420195B MX 420195 B MX420195 B MX 420195B MX 2022000939 A MX2022000939 A MX 2022000939A MX 2022000939 A MX2022000939 A MX 2022000939A MX 420195 B MX420195 B MX 420195B
Authority
MX
Mexico
Prior art keywords
methods
macrocyclic compounds
sting agonists
compounds
disclosed
Prior art date
Application number
MX2022000939A
Other languages
English (en)
Other versions
MX2022000939A (es
Inventor
Amit Kumar Das
Deepak Sahebrao Walke
Ganesh Rajaram Jadhav
Moloy Banerjee
Navnath Popat Karche
Nishant Ramnivasji Gupta
Rajender Kumar Kamboj
Smita Aditya Bhoskar
Vaibhav Madhukar Kalhapure
Venkata P Palle
Vidya Ramdas
Vinod Popatrao Vyavahare
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72422197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX420195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2022000939A publication Critical patent/MX2022000939A/es
Publication of MX420195B publication Critical patent/MX420195B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) o (II) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables, hidratos, solvatos y profármacos de los mismos y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento. (fórmulas)
MX2022000939A 2019-07-22 2020-07-22 Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos MX420195B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201921029556 2019-07-22
IN201921051086 2019-12-10
IN202021003961 2020-01-29
PCT/IB2020/056875 WO2021014365A1 (en) 2019-07-22 2020-07-22 Macrocyclic compounds as sting agonists and methods and uses thereof

Publications (2)

Publication Number Publication Date
MX2022000939A MX2022000939A (es) 2022-04-06
MX420195B true MX420195B (es) 2025-02-10

Family

ID=72422197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000939A MX420195B (es) 2019-07-22 2020-07-22 Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos

Country Status (33)

Country Link
US (1) US12479858B2 (es)
EP (1) EP4004002B1 (es)
JP (1) JP7592689B2 (es)
KR (1) KR20220035955A (es)
CN (1) CN114174303B (es)
AU (1) AU2020319058B2 (es)
BR (1) BR112022001125A2 (es)
CA (1) CA3147397A1 (es)
CL (1) CL2022000145A1 (es)
CO (1) CO2022001814A2 (es)
CR (1) CR20220029A (es)
DK (1) DK4004002T3 (es)
EC (1) ECSP22005485A (es)
ES (1) ES2989915T3 (es)
FI (1) FI4004002T3 (es)
GE (2) GEP20247627B (es)
HR (1) HRP20241222T1 (es)
HU (1) HUE068456T2 (es)
IL (1) IL289740B2 (es)
LT (1) LT4004002T (es)
MA (1) MA56674B1 (es)
MX (1) MX420195B (es)
PE (1) PE20220937A1 (es)
PH (1) PH12022550175A1 (es)
PL (1) PL4004002T3 (es)
PT (1) PT4004002T (es)
RS (1) RS66126B1 (es)
SA (1) SA522431429B1 (es)
SI (1) SI4004002T1 (es)
SM (1) SMT202400399T1 (es)
UA (1) UA129653C2 (es)
WO (1) WO2021014365A1 (es)
ZA (1) ZA202201375B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018246806B2 (en) 2017-03-29 2022-05-12 Ligachem Biosciences Inc. Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
MX420421B (es) 2019-07-22 2025-02-10 Boehringer Ingelheim Int Derivados de n-(6-metoxi)pirizadin-3-il) amina, n-metilo como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
AU2021248635B2 (en) 2020-04-02 2025-10-23 Mersana Therapeutics, Inc. Antibody drug conjugates comprising STING agonists
EP4134098A4 (en) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. Method of cancer therapy
AU2022208054A1 (en) * 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates
TW202302579A (zh) * 2021-03-30 2023-01-16 大陸商北京加科思新藥研發有限公司 用作sting 激動劑的新型化合物及其用途
JP2026501333A (ja) * 2022-12-22 2026-01-14 アキューリアス セラピューティクス ピーティーワイ リミテッド Ｓｔｉｎｇの調節のためのベンズイミダゾール誘導体
AR133167A1 (es) * 2023-07-07 2025-09-03 Hoffmann La Roche Macrociclos para el tratamiento de enfermedad autoinmunitaria
AR133266A1 (es) * 2023-07-19 2025-09-10 Hoffmann La Roche Macrociclos para el tratamiento de enfermedades autoinmunitarias
CN119490423A (zh) * 2023-08-15 2025-02-21 沈阳中化农药化工研发有限公司 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
AU2007257650A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
WO2008090570A1 (en) 2007-01-25 2008-07-31 Panacea Biotec Ltd Novel antimicrobials
TW201000447A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
EP2651926A4 (en) * 2010-12-15 2014-07-09 Abbvie Inc ANTI-VIRAL COMPOUNDS
MX2015007862A (es) 2012-12-28 2016-02-05 Nippon Zoki Pharmaceutical Co Derivado de amida del acido cinamico.
CR20160564A (es) * 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
PE20181884A1 (es) * 2016-04-07 2018-12-07 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
KR102499780B1 (ko) 2016-05-27 2023-02-16 항저우 인노게이트 파마 컴퍼니 리미티드 Fgfr4 저해제인 헤테로 고리 화합물
EA036338B1 (ru) * 2017-02-22 2020-10-28 Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед Гетероциклические амиды, пригодные в качестве модуляторов белков
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
US20200172483A1 (en) 2017-06-22 2020-06-04 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
JP2020524717A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
EP3658138B1 (en) 2017-07-27 2023-04-19 Stingray Therapeutics, Inc. Substituted-3h-imidazo(4,5-c)pyridine and 1h-pyrrolo(2,3-c)pyridine series of novel ectonucleotide pyrophsphatase/phosphodiestrase-1 (enpp1) and stimulator for interferon genes (sting) modulator as cancer immunotherapeutics
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
EP3692033A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
BR112021018947A2 (pt) * 2019-03-28 2022-02-08 Lupin Ltd Compostos macrocíclicos como agonistas de sting

Also Published As

Publication number Publication date
CR20220029A (es) 2022-03-14
EP4004002B1 (en) 2024-07-10
EP4004002A1 (en) 2022-06-01
JP7592689B2 (ja) 2024-12-02
HRP20241222T1 (hr) 2024-12-06
IL289740B2 (en) 2025-10-01
HUE068456T2 (hu) 2024-12-28
SA522431429B1 (ar) 2024-11-11
PE20220937A1 (es) 2022-05-31
US12479858B2 (en) 2025-11-25
UA129653C2 (uk) 2025-06-25
CA3147397A1 (en) 2021-01-28
ZA202201375B (en) 2022-09-28
FI4004002T3 (fi) 2024-10-04
WO2021014365A1 (en) 2021-01-28
IL289740B1 (en) 2025-06-01
CN114174303A (zh) 2022-03-11
PL4004002T3 (pl) 2024-11-18
GEP20247627B (en) 2024-05-27
MA56674B1 (fr) 2024-09-30
CO2022001814A2 (es) 2022-04-29
PH12022550175A1 (en) 2022-11-14
US20220289763A1 (en) 2022-09-15
CL2022000145A1 (es) 2022-09-09
ECSP22005485A (es) 2022-02-25
LT4004002T (lt) 2024-10-25
CN114174303B (zh) 2024-06-25
SMT202400399T1 (it) 2024-11-15
ES2989915T3 (es) 2024-11-28
MX2022000939A (es) 2022-04-06
GEAP202415883A (en) 2024-02-12
BR112022001125A2 (pt) 2022-03-15
KR20220035955A (ko) 2022-03-22
SI4004002T1 (sl) 2024-12-31
AU2020319058A1 (en) 2022-02-17
AU2020319058B2 (en) 2025-10-02
JP2022541330A (ja) 2022-09-22
DK4004002T3 (da) 2024-09-30
RS66126B1 (sr) 2024-11-29
IL289740A (en) 2022-03-01
PT4004002T (pt) 2024-10-07

Similar Documents

Publication Publication Date Title
MX420195B (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CU20200070A7 (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclina
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX2020007265A (es) Derivados de rapamicina.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
EA201691302A1 (ru) Новые гетероциклические соединения
PH12021552263A1 (en) Macrocyclic compounds as sting agonists
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
UY40230A (es) Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden
MX2019008435A (es) Inhibidores selectivos de jak1.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
MX2021007247A (es) Derivados de rapamicina.
PH12014500312A1 (en) Imidazole derivatives as antiviral agents
CY1123185T1 (el) Παραγωγα ινδολιου